Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MYPUV
ADC Name
Y-TR1 GMBS
Synonyms
Y-TR1-GMBS
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 2 Indication(s)
Mature T-cell lymphoma [ICD11:2A90]
Investigative
Pleural mesothelioma [ICD11:2C26]
Investigative
Drug-to-Antibody Ratio
1
Antibody Name
Anti-CD26 mAb YS110
  Antibody Info 
Antigen Name
Dipeptidyl peptidase 4 (DPP4)
  Antigen Info 
Payload Name
Triptolide
  Payload Info 
Therapeutic Target
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
  Target Info 
Linker Name
N-gama-maleimidobutyryl-oxysuccinimide ester (GMBS)
  Linker Info 
Conjugate Type
Random conjugation conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
18
ug/mL
Jurkat cells
T acute lymphoblastic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 18.00 ug/mL Positive CD26 expression (CD26+++/++)
Method Description
Viability assay of Jurkat cells incubated for 72 h with ADC.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
References
Ref 1 Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Cancers (Basel). 2019 Aug 8;11(8):1138. doi: 10.3390/cancers11081138.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.